Novel pyridopyrimidine derivatives as inhibitors of stable toxin a (STa) induced cGMP synthesis

Tanifum, Eric A.; Kots, Alexander Y.; Choi, Byron; Murad, Ferid; Gilbertson, Scott R.

doi:10.1016/j.bmcl.2009.04.024

Cited by 42 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These substances have limited therapeutic use in vivo because they can react with ferrous hemoglobin and myoglobin. We have recently identified a series of pyridopyrimidine derivatives [59] (BPIPP; Fig. 2) as nonspecific indirect inhibitor of guanylyl cyclases which can suppress activation of sGC [60].…”

Section: Activators and Inhibitors Of Soluble Guanylyl Cyclasementioning

confidence: 99%

Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development

Kots

Bian²,

Murad³

2011

CMC

View full text Add to dashboard Cite

show abstract

Section: Activators and Inhibitors Of Soluble Guanylyl Cyclasementioning

confidence: 99%

Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development

Kots

Bian²,

Murad³

2011

CMC

View full text Add to dashboard Cite

show abstract

“…By the same conditions, cyclization between 6‐amino‐uracil derivative with an aldehyde and 1,3‐dicarbonyl compounds furnished the desired dihydropyridopyrimidines 15–17 in good yields (50–86%) (Scheme ) .…”

Section: The Mcrs Synthesis Of Pyridopyrimidinesmentioning

confidence: 99%

Recent Developments in the MCRs Synthesis of Pyridopyrimidines and Spiro‐Pyridopyrimidines

Mamaghani

Nia

2016

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

Because of biological and medicinal properties of pyridopyrimidines, synthesis of these heterocycles has attracted the interest of organic and medicinal chemists. This review focuses on the recent development in the multi‐component synthesis of pyridopyrimidine and spiro‐conjugated pyridopyrimidine systems. The present review describes the literature reports for the period 2000–2015, particularly those that involve the reactions of activated methylene, aldehyde or ketone, and amine in classical and nonclassical conditions.

show abstract

“…Currently, two pharmacological strategies have been employed to specifically counteract the effects of STa: (i) inhibition of GC-C and its signaling; and (ii) inhibition of chloride secretion through CFTR [148,149,150,151,152]. The group of pyridopyrimidine derivatives has been demonstrated to decrease cGMP levels in T84 cells and to decrease STa triggered fluid secretion in an isolated intestinal loop model by inhibition of GC-C [148,149].…”

Section: The Pathophysiology Of Enterotoxin Mediated Diarrheamentioning

confidence: 99%

“…The group of pyridopyrimidine derivatives has been demonstrated to decrease cGMP levels in T84 cells and to decrease STa triggered fluid secretion in an isolated intestinal loop model by inhibition of GC-C [148,149]. Specificity of the substance is limited, as other GC family members (GC-A,B and soluble forms) were also inhibited [148].…”

Section: The Pathophysiology Of Enterotoxin Mediated Diarrheamentioning

confidence: 99%

Toxin Mediated Diarrhea in the 21st Century: The Pathophysiology of Intestinal Ion Transport in the Course of ETEC, V. cholerae and Rotavirus Infection

Kopic

Geibel

2010

Toxins

View full text Add to dashboard Cite

An estimated 4 billion episodes of diarrhea occur each year. As a result, 2–3 million children and 0.5–1 million adults succumb to the consequences of this major healthcare concern. The majority of these deaths can be attributed to toxin mediated diarrhea by infectious agents, such as E. coli, V. cholerae or Rotavirus. Our understanding of the pathophysiological processes underlying these infectious diseases has notably improved over the last years. This review will focus on the cellular mechanism of action of the most common enterotoxins and the latest specific therapeutic approaches that have been developed to contain their lethal effects.

show abstract

Novel pyridopyrimidine derivatives as inhibitors of stable toxin a (STa) induced cGMP synthesis

Cited by 42 publications

References 9 publications

Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development

Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development

Recent Developments in the MCRs Synthesis of Pyridopyrimidines and Spiro‐Pyridopyrimidines

Toxin Mediated Diarrhea in the 21st Century: The Pathophysiology of Intestinal Ion Transport in the Course of ETEC, V. cholerae and Rotavirus Infection

Contact Info

Product

Resources

About